Sun, 26 Sep 2021

JACKSON CENTER, PA / ACCESSWIRE / September 13, 2021 / Halberd Corporation (OTC PINK:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer's Disease from test fluids in laboratory testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication process, replication tests conducted at Youngstown State University (YSU) achieved virtually 100% elimination of the Phosphorylated Tau antigen, which is related to the onset and progression of Alzheimer's Disease and other neurodegenerative diseases!

Dr. William G. Sturrus, Chair of the Physics, Astronomy, Geology and Earth Sciences Department at Youngstown State University, who is overseeing YSU's eradication testing exclaimed, 'Through our earlier, carefully constructed experimentations, we determined the correct combination of factors that can now be replicated to eliminate this target disease antigen from test fluid. The fluid is treated with a specific antibody conjoined to appropriately sized metallic nanoparticles. The antibody is designed with a strong affinity for the disease antigen and attaches itself to the target antigen. The conjoined nanoparticle/antibody/antigen is then exposed to a programed burst of the proper laser light frequency. The laser light excites the nanoparticles, thus generating a sufficient level of heat to destroy the target disease antigen, resulting in elimination of the disease pathogen.'

William A. Hartman, Halberd Corporation's Chairman, President & CEO, stated, 'We are beyond ecstatic with the demonstrated elimination of the Alzheimer's Disease target antigen in our testing to date, thus establishing proof-of-concept! Inasmuch as our testing has successfully determined the critical control variables and application sequences, we believe that we will be successful in eliminating the remaining Alzheimer's Disease-related antigens and inflammatory cytokines in the laboratory. At the conclusion of the interim tests with the inflammatory cytokines, IL-6 and TNF-alpha, which are the principal causal factors of PTSD and CTE (Chronic Traumatic Encephalopathy), we plan to further our discussions with the military and various sports organizations regarding our findings, and offer them the opportunity to participate in the advancement of this promising technology.'

Hartman continued, 'Following the conclusion of all related laboratory experiments, we plan to initiate in-vivo animal tests. Our progress in this regard will be published in subsequent press releases as well as our quarterly CEO Newsletter.'

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies.

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome.

Safe Harbor Notice
Certain statements contained herein are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis. The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.'

SOURCE: Halberd Corporation



View source version on accesswire.com:
https://www.accesswire.com/663682/Halberds-Treatment-Eradicates-Primary-Building-Block-of-Alzheimers-Disease

More Orlando News

Access More

Sign up for The Orlando News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!